Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Return on Equity (2020 - 2025)

Foghorn Therapeutics has reported Return on Equity over the past 6 years, most recently at 0.78% for Q4 2025.

  • Quarterly results put Return on Equity at 0.78% for Q4 2025, down 156.0% from a year ago — trailing twelve months through Dec 2025 was 0.78% (down 156.0% YoY), and the annual figure for FY2025 was 1.01%, down 40.0%.
  • Return on Equity for Q4 2025 was 0.78% at Foghorn Therapeutics, down from 0.9% in the prior quarter.
  • Over the last five years, Return on Equity for FHTX hit a ceiling of 9.19% in Q1 2023 and a floor of 8.91% in Q4 2022.
  • Median Return on Equity over the past 5 years was 0.98% (2024), compared with a mean of 0.54%.
  • Biggest five-year swings in Return on Equity: surged 1044bps in 2023 and later plummeted -813bps in 2024.
  • Foghorn Therapeutics' Return on Equity stood at 1.15% in 2021, then crashed by -672bps to 8.91% in 2022, then soared by 116bps to 1.46% in 2023, then skyrocketed by 60bps to 2.35% in 2024, then crashed by -67bps to 0.78% in 2025.
  • The last three reported values for Return on Equity were 0.78% (Q4 2025), 0.9% (Q3 2025), and 1.12% (Q2 2025) per Business Quant data.